Penn Researchers Show that Inhibiting Cholesterol-Associated Protein Reduces High-Risk Blockages in Arteries

September 23, 2008

Studies in animal model point way toward new class of heart-disease medication

PHILADELPHIA - Using the drug darapladib, researchers at the University of Pennsylvania School of Medicine and colleagues have inhibited a cholesterol-and immune system-associated protein, thereby reducing the development of heart-disease plaques that may cause death, heart attacks, and strokes in a pig model of atherosclerosis and diabetes. The study appeared online this week in Nature Medicine.

"We've used a model that closely mimics clinical disease," says first author Robert L. Wilensky, MD, Director of Experimental Interventional Cardiology and Professor of Medicine at the Penn Cardiovascular Institute. "The study shows that darapladib is useful in reducing atherosclerosis but more importantly those blockages that are thought to cause death and heart attacks."

Atherosclerosis, or hardening of the arteries, is the most common cause of heart attack, stroke, and death from cardiovascular disease, and has long been thought of as a type of chronic inflammation. An early first step in the build-up of the plaques associated with atherosclerosis is the accumulation of low-density lipoproteins (LDLs), the "bad" cholesterol, on artery walls. When LDLs are oxidized by the body, they attract immune cells and lipids to the site of the build-up.

Problems arise when the plaques grow to form a lesion characterized by a thin fibrous cap and a lipid-filled core of dying cells. These unstable plaques are prone to rupture, which can then lead to heart attack, stroke, and death.

A molecule called lipoprotein-associated phospholipase A2 (Lp-PLA2) is connected with LDLs circulating in the blood. Elevated levels of Lp-PLA2 in the blood predict an increased risk of heart disease events and are related to the development of the necrotic core of plaques. Darapladib specifically inhibits Lp-PLA2.

"The results are exciting," says Wilensky. "First, darapladib reduced the overall amount and size of plaques that block the coronary arteries of animals in the study. More importantly, it reduced the number and size of the type of advanced plaques that cause heart attacks and strokes. "

These advanced plaques have a thin cap and large core filled with cellular debris from inflammatory-immune cells that engorge themselves on cholesterol. If unstable plaques come into contact with blood, blood clots that develop from this contact constrict flow, which can lead to stroke and heart attack. Darapladib stabilizes these dangerous plaques by decreasing the size of the core and reducing the number of inflammatory-immune cells present within the plaque. Darapladib also decreased the expression of genes involved in enlisting immune cells involved in the inflammatory response associated with atherosclerosis.

"The aha moment came when we saw the profound difference in plaque composition in animals given medication versus those not given darapladib, although the high cholesterol levels in the pig model remained the same in both groups," says Wilensky. "This study took cholesterol out of the equation and let us evaluate the effects of inflammation on the development of atherosclerosis."

Recently, darapladib has been tested in a human clinical trial in Europe, which showed similar findings. GlaxoSmithKline (GSK) Inc., who provided the darapladib for the study, is planning a Phase 1 safety and efficacy trial with darapladib in humans in the near future. Penn will be one site in this proposed multi-center clinical trial. This study was supported, in part, by funding from GlaxoSmithKline, over the last two years totaling about $1.5 million, through an industry-academic alliance called the Alternative Drug Discovery Initiative at the Penn School of Medicine. Co-author Emile Mohler, III, has a position on a steering committee as a National Coordinator for the Phase III GSK trial for darapladib.

In addition to other Penn co-authors Damir Hamamdzic, Daniel J. Pelchovitz, and Jisheng Yang, colleagues from Thomas Jefferson University, GlaxSmithKline, Southhampton General Hospital (UK), and the University of Washington were also co-authors.

University of Pennsylvania

---

---

	Atherosclerosis by Sarah Jane George (Editor), Jason Johnson (Editor) Covering the most devastating disease in the Western world, this handbook and ready reference provides a comprehensive account of the different stages and factors in the development of the atherosclerotic plaque. Each chapter is written by experts in the field and highlights the role of specific mediators of atherosclerotic plaque development, as well as potential therapeutic targets. A large amount of this up-to-date information is conveyed by way of tables and schematic figures, in a readily comprehensible manner. A must-have for master and PhD students, researchers, MDs and lecturers in vascular biology and cardiology, as well as for academics and scientists in the pharmaceutical industry.
	Asymptomatic Atherosclerosis: Pathophysiology, Detection and Treatment (Contemporary Cardiology) by Morteza Naghavi (Editor) Despite recent advances in the diagnosis and treatment of symptomatic atherosclerosis, available traditional screening methods for early detection and treatment of asymptomatic coronary artery disease are grossly insufficient and fail to identify the majority of victims prior to the onset of a life-threatening event. In Asymptomatic Atherosclerosis: Pathophysiology, Detection and Treatment, Dr. Morteza Naghavi and leading authorities from the Society for Heart Attack Prevention and Eradication (SHAPE) present a new paradigm for the screening and primary prevention of asymptomatic atherosclerosis. The text focuses on accurate, yet underutilized, measures of subclinical atherosclerosis, notably coronary artery calcium scanning and carotid intima-media thickness measurement. The authors...
	Dyslipidemia and Atherosclerosis Essentials 2009 by Christie M. Ballantyne (Author), James H. O'Keefe Jr. (Author), Antonio M. Gotto Jr. (Author) The World's Leading Experts Provide all the 'Essentials' Needed to Manage Patients in the Office, on the Ward, and in the Intensive Care Unit! Written by key opinion leaders in the field of cardiology, Dyslipidemia Essentials integrates the latest clinical guidelines and trials into a practical step-by-step guide to the management of dyslipidemia. Important clinical trials, common management pitfalls, and other cardiovascular risk reduction measures are also emphasized. Topics include: Step-by-step guide to intensive LDL lowering; NCEP ATP III and AHA/ACC guideline Updates; Treatment of low HDL cholesterol and elevated triglyceride; 73 dyslipidemia trials and 17 drug summaries
	Atherosclerosis: Experimental Methods and Protocols (Methods in Molecular Medicine) by Angela F. Drew (Editor) In Atherosclerosis: Experimental Methods and Protocols, Angela Drew and a panel of experts have assembled a comprehensive collection of traditional and cutting-edge techniques for investigating this disease and its possible treatments. Each readily reproducible method includes step-by-step instructions and practical information regarding sample collection, the choice of animal model system, experimental design, and practical data analysis techniques. Comprehensive and richly detailed, Atherosclerosis: Experimental Methods and Protocols enables all biomedical investigators to select those optimized techniques that may be most fruitfully used to study the development, progression, and treatment of atherosclerotic lesions today.
	Inflammation and Atherosclerosis by Georg Wick (Editor), Cecilia Grundtman (Editor) It has been known for over 150 years that hallmarks of inflammation can be observed in the wall of atherosclerotic vessels. It was, however, not clear if this inflammation is the cause or the consequence of atherogenesis. More recently, it has become evident that inflammation mediated both by innate and adaptive immunity is instrumental even in the earliest stages of the development of atherosclerotic lesions, i.e., that it plays an important pathogenetic role. In this volume, international experts in the field discuss the pathogenetic, diagnostic, preventive and possible therapeutic relevance of inflammation in atherogenesis. This book is intended for researchers and physicians in the fields of vascular biology, immunology and atherosclerosis.
	Biochemistry of Atherosclerosis (Advances in Biochemistry in Health and Disease) by Sukhinder C. Kaur (Editor) This book covers many aspects of atherogenesis, with particular emphasis on lipid and lipoprotein metabolism. It includes all aspects of the regulation of cholesterol homeostasis and the importance of each pathway. Also explored are the roles of nuclear hormone receptors on lipid and lipoprotein metabolism and their complex roles in atherogenesis. The book further discusses how genetic studies can help understand the complexities that mediate these aspects of atherogenesis.
	CATHETER-BASED TREATMENT OF ATHEROSCLEROSIS: Options for effective percutaneous intervention are plentiful From the initial balloon catheters, percutaneous ... protection devices. (Postgraduate Medicine) by JTE Multimedia Hopes for successful utilization, minimal complications, and improved patient comfort ride on interventional cardiology. A variety of devices are available or in development for percutaneous treatment of atherosclerotic disease. Here, Dr Khalil reviews devices with a long history in cardiology as well as newer arrivals and discusses their best-use parameters and appropriate application. He also summarizes the outcome data on their use. Original Publication Date: March 2004
	C-REACTIVE PROTEIN AS A NOVEL BIOMARKER: Reactant can flag atherosclerosis and help predict cardiac events Exploring the role of this acute phase response ... disease. (Postgraduate Medicine) by JTE Multimedia C-reactive protein (CRP) is a relatively nonspecific marker of inflammation. However, it can be used to monitor the severity and progression of some well-defined cardiovascular diseases. For example, it can predict serious events in patients with coronary artery disease (CAD) who are hospitalized with acute coronary syndrome, myocardial infarction (MI), or advanced peripheral vascular disease. In this article, the authors review the role of CRP in the diagnosis, monitoring, and treatment of various forms of ischemic and inflammatory cardiovascular disease. Original Publication Date: December 2003
	Oophorectomy Increases Risk for Atherosclerosis.(Brief Article): An article from: Family Practice News by Doug Brunk (Author) This digital document is an article from Family Practice News, published by International Medical News Group on February 1, 2001. The length of the article is 348 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Oophorectomy Increases Risk for Atherosclerosis.(Brief Article) Author: Doug Brunk Publication: Family Practice News (Magazine/Journal) Date: February 1, 2001 Publisher: International Medical News Group Volume: 31 Issue: 3 Page: 25 Article Type: Brief Article Distributed by Thomson...
	Metabolic syndrome predicts subclinical atherosclerosis in adults.(Across Specialties): An article from: Clinical Psychiatry News by Bruce Jancin (Author) This digital document is an article from Clinical Psychiatry News, published by Thomson Gale on July 1, 2005. The length of the article is 539 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Metabolic syndrome predicts subclinical atherosclerosis in adults.(Across Specialties) Author: Bruce Jancin Publication: Clinical Psychiatry News (Magazine/Journal) Date: July 1, 2005 Publisher: Thomson Gale Volume: 33 Issue: 7 Page: 59(1) Distributed by Thomson...